Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection

M. Julsgaard, L.A. Christensen, P.R. Gibson, R.B. Gearry, J. Fallingborg, C.L. Hvas, B.M. Bibby, N. Uldbjerg, W.R. Connell, O. Rosella, A. Grosen, S.J. Brown, J. Kjeldsen, S. Wildt, L. Svenningsen, M.P. Sparrow, A. Walsh, S.J. Connor, G. Radford-Smith, Ian LawranceJ.M. Andrews, K. Ellard, S.J. Bell

    Research output: Contribution to journalArticlepeer-review

    190 Citations (Scopus)


    © 2016 AGA InstituteBackground & Aims Little is known about in utero exposure to and postnatal clearance of anti–tumor necrosis factor (anti-TNF) agents in neonates. We investigated the concentrations of adalimumab and infliximab in umbilical cord blood of newborns and rates of clearance after birth, and how these correlated with drug concentrations in mothers at birth and risk of infection during the first year of life. Methods We performed a prospective study of 80 pregnant women with inflammatory bowel diseases at tertiary hospitals in Denmark, Australia, and New Zealand from March 2012 through November 2014: 36 received adalimumab and 44 received infliximab; 39 received concomitant thiopurines during pregnancy. Data were collected from medical records on disease activity and treatment before, during, and after pregnancy. Concentrations of anti-TNF agents were measured in blood samples from women at delivery and in umbilical cords, and in infants for every 3 months until the drug was no longer detected. Results The time from last exposure to anti-TNF agent during pregnancy correlated inversely with the concentration of the drugs in the umbilical cord (adalimumab: r = -0.64, P =.0003; infliximab: r = -0.77, P
    Original languageEnglish
    Pages (from-to)110-119
    Number of pages10
    Issue number1
    Publication statusPublished - 1 Jul 2016


    Dive into the research topics of 'Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection'. Together they form a unique fingerprint.

    Cite this